@article{be8aeee31c7049bf8d4682e3b2029e35,
title = "Low-dose combination blood pressure pharmacotherapy to improve treatment effectiveness, safety, and efficiency",
author = "Huffman, {Mark D.} and Gbenga Ogedegbe and Marc Jaffe",
note = "Funding Information: completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Dr Huffman reported receiving funding from the World Heart Federation to serve as its senior program advisor for the emerging leaders program, which is funded through unrestricted educational grants from Boehringer Ingelheim and Novartis with previous support from Bupa and AstraZeneca; funding support from the American Heart Association, Verily, and AstraZeneca; and being co-leader of a clinical trial evaluating the effects of quarter-dose, 4-drug blood pressure–lowering combination therapy, which is sponsored by the National Heart, Lung, and Blood Institute. No other disclosures were reported.",
year = "2018",
month = aug,
day = "14",
doi = "10.1001/jama.2018.10649",
language = "English (US)",
volume = "320",
pages = "552--554",
journal = "JAMA - Journal of the American Medical Association",
issn = "0098-7484",
publisher = "American Medical Association",
number = "6",
}